SG11202000402PA - T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof - Google Patents
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereofInfo
- Publication number
- SG11202000402PA SG11202000402PA SG11202000402PA SG11202000402PA SG11202000402PA SG 11202000402P A SG11202000402P A SG 11202000402PA SG 11202000402P A SG11202000402P A SG 11202000402PA SG 11202000402P A SG11202000402P A SG 11202000402PA SG 11202000402P A SG11202000402P A SG 11202000402PA
- Authority
- SG
- Singapore
- Prior art keywords
- cells
- methods
- receptor
- chimeric antigen
- deficient chimeric
- Prior art date
Links
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
- 230000002950 deficient Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762543735P | 2017-08-10 | 2017-08-10 | |
PCT/US2018/046137 WO2019032916A1 (en) | 2017-08-10 | 2018-08-09 | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000402PA true SG11202000402PA (en) | 2020-02-27 |
Family
ID=65231396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000402PA SG11202000402PA (en) | 2017-08-10 | 2018-08-09 | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
Country Status (10)
Country | Link |
---|---|
US (3) | US20190038733A1 (en) |
EP (1) | EP3665270A4 (en) |
JP (1) | JP2020530291A (en) |
KR (1) | KR20200035304A (en) |
CN (1) | CN111247241A (en) |
AU (1) | AU2018313939A1 (en) |
CA (1) | CA3071282A1 (en) |
SG (1) | SG11202000402PA (en) |
WO (1) | WO2019032916A1 (en) |
ZA (1) | ZA202000852B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
CN112175911B (en) | 2014-05-15 | 2023-10-13 | 新加坡国立大学 | Modified natural killer cells and uses thereof |
AU2016216149B2 (en) | 2015-02-06 | 2022-03-31 | National University Of Singapore | Methods for enhancing efficacy of therapeutic immune cells |
KR20190085528A (en) | 2016-11-22 | 2019-07-18 | 싱가포르국립대학교 | Blocking chimeric antigen receptors and CD7 expression for immunotherapy of T-cell malignancies |
WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
MX2019011514A (en) | 2017-03-27 | 2020-01-27 | Nat Univ Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy. |
US20190038733A1 (en) | 2017-08-10 | 2019-02-07 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
SG11202104334SA (en) * | 2018-11-14 | 2021-05-28 | MediSix Therapeutics Pte Ltd | Two-gene vectors for generating car-t cells and uses thereof |
JOP20210298A1 (en) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | Methods and compositions for preventing type 1 diabetes |
BR112022006923A2 (en) * | 2019-10-11 | 2022-07-05 | Univ Leland Stanford Junior | RECOMBINANT POLYPEPTIDES FOR ADJUSTABLE CELL LOCALIZATION |
JP2023509590A (en) | 2019-12-19 | 2023-03-09 | ▲蘇▼州方▲徳▼▲門▼▲達▼新▲薬▼▲開▼▲発▼有限公司 | Engineered T cells, their preparation and applications |
CN113088495A (en) * | 2020-01-09 | 2021-07-09 | 苏州方德门达新药开发有限公司 | Engineered T cells, their preparation and use |
CN111944850B (en) * | 2020-08-28 | 2023-03-31 | 澳门大学 | Preparation method of cell for expressing anti-CD22 chimeric antigen receptor and PD-L1 blocking protein, expression vector and application |
EP4178986A4 (en) * | 2020-09-13 | 2024-01-10 | Shandong Boan Biotechnology Co Ltd | Downregulation of membrane-bound proteins by receptor tac technology |
WO2024036285A2 (en) * | 2022-08-11 | 2024-02-15 | Medisix Therapeutics, Inc. | Engineered immune cells expressing a car and a plurality of protein expression blockers and uses thereof |
WO2024097797A1 (en) * | 2022-11-02 | 2024-05-10 | Medisix Therapeutics, Inc. | Blockade of cd3 expression and chimeric antigen receptors for immunotherapy |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
EP1015616A2 (en) | 1997-09-19 | 2000-07-05 | Dana Farber Cancer Institute, Inc. | Intrabody-mediated control of immune reactions |
AU2002361390A1 (en) | 2001-12-14 | 2003-06-30 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Anti-cd7 immunotoxin as fusion protein |
US20090191213A9 (en) | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
AU2004253630B2 (en) | 2003-07-02 | 2010-11-25 | Innate Pharma S.A.S. | Methods for the production and cytotoxicity evaluation of KIR2DL NK-receptor antibodies |
WO2005017163A2 (en) | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Phenotypic knockout of cell-surface proteins |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
JP5112863B2 (en) | 2004-07-01 | 2013-01-09 | ノヴォ ノルディスク アー/エス | Human anti-KIR antibody |
EP1814567A4 (en) | 2004-10-27 | 2009-05-06 | Medimmune Inc | Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections |
EP3072522B1 (en) | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
AU2006302254B2 (en) | 2005-10-06 | 2011-05-26 | Xencor, Inc. | Optimized anti-CD30 antibodies |
MX2009008909A (en) | 2007-03-01 | 2009-08-28 | Symphogen As | Recombinant anti-epidermal growth factor receptor antibody compositions. |
EP2185574B1 (en) | 2007-09-07 | 2013-05-08 | Agensys, Inc. | Antibodies and related molecules that bind to 24p4c12 proteins |
BRPI0908508A2 (en) | 2008-01-24 | 2016-03-22 | Novo Nordisk As | humanized anti-human nkg2a monoclonal antibody |
WO2011047146A2 (en) | 2009-10-14 | 2011-04-21 | Centocor Ortho Biotech Inc. | Methods of affinity maturing antibodies |
WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
MX347078B (en) | 2010-12-09 | 2017-04-10 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer. |
SI4019041T1 (en) | 2012-07-13 | 2023-04-28 | The Trustees Of The University Of Pennsylvania | Toxicity management for anti-tumor activity of cars |
EP3763810A3 (en) | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
KR101521224B1 (en) | 2012-12-20 | 2015-05-19 | 한양대학교 산학협력단 | Humanized single chain fragment antibody(scFv) carrier specific for T cell |
JP2016503655A (en) | 2012-12-27 | 2016-02-08 | アデュロ バイオテック,インコーポレイテッド | Signal peptide fusion partner facilitating expression of the antigenic sequence of Listeria, its preparation method and its use |
KR20220100093A (en) | 2013-02-06 | 2022-07-14 | 안트로제네시스 코포레이션 | Modified t lymphocytes having improved specificity |
MX2016006057A (en) | 2013-11-21 | 2016-11-14 | Ucl Business Plc | Cell. |
GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
EP3169773B1 (en) | 2014-07-15 | 2023-07-12 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
BR112017007003A2 (en) | 2014-10-07 | 2017-12-19 | Cellectis | method for modulating carbon-induced immune cell activity |
CA2964948A1 (en) | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
PL3560953T3 (en) | 2014-12-24 | 2024-05-13 | Autolus Limited | Cell |
AU2016216149B2 (en) * | 2015-02-06 | 2022-03-31 | National University Of Singapore | Methods for enhancing efficacy of therapeutic immune cells |
PL3261651T3 (en) | 2015-02-27 | 2022-08-22 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
CN107073138B (en) | 2015-03-02 | 2018-06-29 | 上海斯丹赛生物技术有限公司 | Reduce the immunological tolerance induced by PD-L1 |
CN108350445A (en) | 2015-06-19 | 2018-07-31 | 麻省理工学院 | Immunotherapy of tumors |
MA42895A (en) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | MODIFIED CELLS FOR ADOPTIVE CELL THERAPY |
SG10201912792YA (en) | 2015-10-06 | 2020-02-27 | Univ Minnesota | Therapeutic compounds and methods |
US11390658B2 (en) | 2016-06-06 | 2022-07-19 | St. Jude Children's Research Hospital | Anti-CD7 chimeric antigen receptor and method of use thereof |
US20200283534A1 (en) | 2016-06-24 | 2020-09-10 | iCell Gene Therapeuticics LLC | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
CA2937157A1 (en) * | 2016-07-25 | 2018-01-25 | Ucl Business Plc | Protein-based t-cell receptor knockdown |
KR102546839B1 (en) | 2016-08-03 | 2023-06-23 | 워싱턴 유니버시티 | Gene editing of CAR-T cells for the treatment of T-cell malignancies using chimeric antigen receptors |
GB201622044D0 (en) | 2016-12-22 | 2017-02-08 | Ucl Business Plc | T cell-targeted T cells |
AU2018208614A1 (en) | 2017-01-10 | 2019-07-11 | The General Hospital Corporation | Modified T cells and methods of their use |
US20190038733A1 (en) | 2017-08-10 | 2019-02-07 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
-
2018
- 2018-08-09 US US16/100,120 patent/US20190038733A1/en not_active Abandoned
- 2018-08-09 WO PCT/US2018/046137 patent/WO2019032916A1/en unknown
- 2018-08-09 US US16/100,117 patent/US11648269B2/en active Active
- 2018-08-09 CA CA3071282A patent/CA3071282A1/en active Pending
- 2018-08-09 CN CN201880057927.5A patent/CN111247241A/en active Pending
- 2018-08-09 SG SG11202000402PA patent/SG11202000402PA/en unknown
- 2018-08-09 EP EP18844536.5A patent/EP3665270A4/en not_active Withdrawn
- 2018-08-09 JP JP2020506799A patent/JP2020530291A/en active Pending
- 2018-08-09 AU AU2018313939A patent/AU2018313939A1/en not_active Abandoned
- 2018-08-09 KR KR1020207006870A patent/KR20200035304A/en not_active Application Discontinuation
-
2020
- 2020-02-10 ZA ZA2020/00852A patent/ZA202000852B/en unknown
-
2023
- 2023-04-03 US US18/295,226 patent/US20230364140A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3665270A4 (en) | 2021-04-21 |
ZA202000852B (en) | 2023-10-25 |
US20190038733A1 (en) | 2019-02-07 |
US20230364140A1 (en) | 2023-11-16 |
US11648269B2 (en) | 2023-05-16 |
US20190046571A1 (en) | 2019-02-14 |
EP3665270A1 (en) | 2020-06-17 |
CN111247241A (en) | 2020-06-05 |
CA3071282A1 (en) | 2019-02-14 |
JP2020530291A (en) | 2020-10-22 |
WO2019032916A1 (en) | 2019-02-14 |
KR20200035304A (en) | 2020-04-02 |
AU2018313939A1 (en) | 2020-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202000852B (en) | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof | |
IL261941A (en) | Chimeric antigen and t cell receptors and methods of use | |
EP3579877A4 (en) | Chimeric t cell antigen receptors and methods of use thereof | |
IL283734A (en) | Chimeric antigen receptors and car-t cells and methods of use | |
IL257297A (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
IL280718A (en) | T cell receptor constructs and uses thereof | |
IL284216A (en) | Anti-transferrin receptor antibodies and uses thereof | |
SG10201913579WA (en) | Chimeric antibody/t-cell receptor constructs and uses thereof | |
EP3564266A4 (en) | Novel chimeric antigen receptor and use thereof | |
DK3365364T3 (en) | Chimeric antibody/T cell receptor constructs and uses thereof | |
EP3645574A4 (en) | Chimeric antibody immune effctor cell engagers and methods of use thereof | |
HK1222677A1 (en) | Cd123-specific chimeric antigen receptor redirected t cells and methods of their use cd123 t | |
HK1256130A1 (en) | T cells for expression of chimeric antigen receptors and other receptors | |
IL280029A (en) | Ror-1 specific chimeric antigen receptors and uses thereof | |
EP3630980A4 (en) | Chimeric antigen receptor cell preparation and uses thereof | |
IL286038A (en) | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy | |
EP3887509A4 (en) | Chimeric antigen receptor factories and methods of use thereof | |
EP3443076A4 (en) | Compositions and methods of chimeric alloantigen receptor t cells | |
IL275040A (en) | T-cells comprising two different chimeric antigen receptors and uses thereof | |
SG11202101169PA (en) | Chimeric antigen receptor that binds hla-dr and car-t cell | |
ZA202008065B (en) | Muc16 specific chimeric antigen receptors and uses thereof | |
DK3720883T3 (en) | T CELL COMPREHENSIVE CHIMERIC ANTI-CD38 AND ANTI-CD138 ANTIGEN RECEPTORS AND USES THEREOF | |
EP3609536A4 (en) | Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor | |
IL273538A (en) | Anti-trkb monoclonal antibodies and methods of use | |
GB2585607B (en) | Chimeric antigen receptor and application thereof |